Drug intelligence / Profile preview

NPX-CNS

Development stage: Preclinical
Lead developer: Neurophoenix
Modality: Recombinant Proteins and Enzymes

Overview

NPX-CNS is a preclinical-stage CNS-targeting protein being developed by Neurophoenix for the treatment of non-inherited neurodegenerative diseases. The drug utilizes a cell-penetrating molecule (CPM) platform, inspired by the Rabies virus glycoprotein mechanism, to deliver the therapeutic protein across the blood-brain barrier. Its mechanism of action involves the inactivation of PTEN (Phosphatase and tensin homolog) by disrupting the protein-protein interaction between PTEN and the kinases MAST1 and MAST2. By inhibiting this interaction, NPX-CNS aims to promote neuronal survival and regeneration in the central nervous system.

Targets

MAST2 (Microtubule-associated serine/threonine-protein kinase 2)MAST1 (Cytoplasmic linker associated protein 1)

Beyond the preview

Go deeper on NPX-CNS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPX-CNS.

Explore the full profile